Reports Q4 revenue $1.7M, consensus $5.35M. “Ocuphire had a successful 2023, with notable achievements on the regulatory and development fronts, paving the way for further progress in the year ahead,” said George Magrath, M.D., M.B.A., M.S., CEO of Ocuphire. “Our strategic focus is on the advancement of our retina pipeline, and we are preparing our late-stage clinical program to progress APX3330 in diabetic retinopathy. We believe APX3330 may represent a promising oral treatment option for delaying disease progression in patients with non-proliferative diabetic retinopathy who otherwise are monitored and untreated until they progress to sight-threatening disease.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OCUP:
- OCUP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Ocuphire Pharma to Present in the BIO CEO & Investor Conference
- Ocuphire Pharma Welcomes Nirav Jhaveri as New CFO
- Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Ocuphire Pharma appoints Jayagopal as CSDO, Jhaveri as CFO
